ArticleNeurochemical research2026
Morin Improves Cognitive Deficits in an in Vivo Model of Vascular Dementia by Modulating the N-methyl-D-aspartate Receptor Signaling Pathways.
Article in Neurochemical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The research on the pathoetiology of vascular dementia (VaD) highlights a notable deficiency in effective therapies within present medical practices. Morin exhibits promising therapeutic benefits due to its strong antioxidant and anti-inflammatory properties. However, its specific functions and mechanisms in VaD require further elucidation. In this study, VaD animals were established by permanent bilateral common carotid artery occlusion (2VO). Cognitive functions and behavioral analysis were performed in rats. Moreover, the state of oxidative stress, inflammation, and apoptosis was evaluated. Western blotting and ELISA were performed to investigate synaptic plasticity-related proteins, such as SYP, PSD-95, and NMDA receptor proteins (NR1, NR2A, NR2B). The results revealed that morin reduced oxidative stress in the hippocampus by lowering MDA and recombinant reactive oxygen species modulator 1 (Romo-1) levels, while simultaneously enhancing the activities of SOD and GPx. In addition, morin increased the levels of anti-inflammatory cytokines (IL-10 and IL-4), while reducing the levels of pro-inflammatory cytokines (IL-1β and IL-6), and suppressed apoptosis through downregulation of caspase 3 and upregulation of BCL-2. Additionally, morin promoted the expression of PSD95, SYP, and NMDAR proteins in animals with VaD. The obtained data suggest that morin is associated with improved cognitive impairments in VaD rats, which may be mediated by the reduction of apoptosis, oxidative stress, and inflammation in the hippocampus, as well as by restoring the signaling of NMDARs.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.